State of Wisconsin Investment Board bought a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm bought 56,000 shares of the biotechnology company’s stock, valued at approximately $311,000. State of Wisconsin Investment Board owned about 0.07% of BioCryst Pharmaceuticals as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in BioCryst Pharmaceuticals by 49.1% during the 1st quarter. Vanguard Group Inc. now owns 5,011,763 shares of the biotechnology company’s stock worth $42,098,000 after buying an additional 1,651,292 shares during the last quarter. RA Capital Management LLC lifted its holdings in BioCryst Pharmaceuticals by 16.7% during the 1st quarter. RA Capital Management LLC now owns 3,489,795 shares of the biotechnology company’s stock worth $29,314,000 after buying an additional 500,000 shares during the last quarter. State Street Corp lifted its holdings in BioCryst Pharmaceuticals by 8.6% during the 1st quarter. State Street Corp now owns 2,272,104 shares of the biotechnology company’s stock worth $19,083,000 after buying an additional 179,216 shares during the last quarter. FMR LLC lifted its holdings in BioCryst Pharmaceuticals by 97.5% during the 1st quarter. FMR LLC now owns 1,456,885 shares of the biotechnology company’s stock worth $12,238,000 after buying an additional 719,162 shares during the last quarter. Finally, Bogle Investment Management L P DE bought a new position in BioCryst Pharmaceuticals during the 1st quarter worth approximately $9,058,000. 86.23% of the stock is currently owned by institutional investors.

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) opened at 5.16 on Friday. BioCryst Pharmaceuticals, Inc. has a one year low of $3.75 and a one year high of $9.25. The company has a 50 day moving average price of $4.86 and a 200 day moving average price of $6.09. The company’s market cap is $415.01 million.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The company had revenue of $3.10 million for the quarter, compared to analyst estimates of $5.79 million. BioCryst Pharmaceuticals had a negative net margin of 160.97% and a negative return on equity of 276.62%. The firm’s revenue for the quarter was down 35.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.22) earnings per share. Equities research analysts expect that BioCryst Pharmaceuticals, Inc. will post ($0.75) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/15/56000-shares-in-biocryst-pharmaceuticals-inc-bcrx-purchased-by-state-of-wisconsin-investment-board.html.

A number of research analysts have commented on the company. Noble Financial reaffirmed a “buy” rating on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 8th. ValuEngine downgraded BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Zacks Investment Research downgraded BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 10th. Royal Bank Of Canada assumed coverage on BioCryst Pharmaceuticals in a report on Thursday. They set a “sector perform” rating on the stock. Finally, HC Wainwright reaffirmed a “buy” rating on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 8th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the company. BioCryst Pharmaceuticals has a consensus rating of “Hold” and an average target price of $9.13.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX).

Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.